|Bid||20.02 x 1800|
|Ask||20.60 x 800|
|Day's Range||19.10 - 24.47|
|52 Week Range||1.39 - 38.75|
|Beta (5Y Monthly)||2.81|
|PE Ratio (TTM)||N/A|
|Earnings Date||Oct 20, 2021 - Oct 25, 2021|
|Forward Dividend & Yield||N/A (N/A)|
|Ex-Dividend Date||Mar 28, 2007|
|1y Target Est||N/A|
WOBURN, Mass., July 22, 2021 (GLOBE NEWSWIRE) -- NeuroMetrix, Inc. (Nasdaq: NURO) today reported financial and business highlights for the quarter ended June 30, 2021. The Company is a leader in proprietary non-invasive medical devices for the diagnosis and treatment of pain and neurological disorders. Highlights: Revenue of $2.2 million improved 63% from $1.4 million in Q2 2020. The Q2 2020 results were adversely affected by a pandemic-related decline in customer orders. Gross margin on revenue
Just because a business does not make any money, does not mean that the stock will go down. Indeed, NeuroMetrix...
Stocks moving in premarket trading Wednesday include Chembio, NeuroMetrix, Johnson & Johnson, Coke and Verizon.